{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:24:14Z","timestamp":1722889454350},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T00:00:00Z","timestamp":1480377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T00:00:00Z","timestamp":1480377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s12185-016-2146-4","type":"journal-article","created":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T05:49:03Z","timestamp":1480398543000},"page":"470-477","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan"],"prefix":"10.1007","volume":"105","author":[{"given":"Michinori","family":"Ogura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naokuni","family":"Uike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Uoshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Suzumiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsutoshi","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohmachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"For the Japanese Bendamustine Lymphoma Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,29]]},"reference":[{"key":"2146_CR1","doi-asserted-by":"crossref","unstructured":"Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25:iii76\u201382.","DOI":"10.1093\/annonc\/mdu200"},{"key":"2146_CR2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/leu.2014.91","volume":"28","author":"W Hiddemann","year":"2014","unstructured":"Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia. 2014;28:1388\u201395.","journal-title":"Leukemia"},{"key":"2146_CR3","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","volume":"127","author":"BS Kahl","year":"2016","unstructured":"Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood. 2016;127:2055\u201363.","journal-title":"Blood"},{"key":"2146_CR4","doi-asserted-by":"crossref","unstructured":"Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25:iii83\u201392.","DOI":"10.1093\/annonc\/mdu264"},{"key":"2146_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1038\/leu.2014.171","volume":"28","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Ferrero S, Hermine O. How to manage mantle cell lymphoma. Leukemia. 2014;28:2117\u201330.","journal-title":"Leukemia"},{"key":"2146_CR6","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, W\u00f6rmann B, D\u00fchrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23:1984\u201392.","journal-title":"J Clin Oncol"},{"key":"2146_CR7","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","volume":"27","author":"BD Cheson","year":"2009","unstructured":"Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009;27:1492\u2013501.","journal-title":"J Clin Oncol"},{"key":"2146_CR8","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2005;23:3383\u20139.","journal-title":"J Clin Oncol"},{"key":"2146_CR9","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26:4473\u20139.","journal-title":"J Clin Oncol"},{"key":"2146_CR10","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin\u2019s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008; 26 204\u201310.","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"2146_CR11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","volume":"116","author":"BS Kahl","year":"2010","unstructured":"Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010;116:106\u201314.","journal-title":"Cancer"},{"key":"2146_CR12","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1111\/j.1349-7006.2010.01633.x","volume":"101","author":"M Ogura","year":"2010","unstructured":"Ogura M, Uchida T, Taniwaki M, Ando K, Watanabe T, Kasai M, et al. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101:2054\u20138.","journal-title":"Cancer Sci"},{"key":"2146_CR13","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/j.1349-7006.2010.01635.x","volume":"101","author":"K Ohmachi","year":"2010","unstructured":"Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010;101:2059\u201364.","journal-title":"Cancer Sci"},{"key":"2146_CR14","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"2146_CR15","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944\u201352.","journal-title":"Blood"},{"key":"2146_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3109\/10428194.2015.1091934","volume":"57","author":"S Luminari","year":"2016","unstructured":"Luminari S, Goldaniga M, Cesaretti M, Orsucci L, Tucci A, Pulsoni A, et al. A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2016;57:880\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2146_CR17","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","volume":"1","author":"A Salar","year":"2014","unstructured":"Salar A, Domingo-Domenech E, Panizo C, Nicol\u00e1s C, Bargay J, Munta\u00f1ola A, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014;1:e104\u201311.","journal-title":"Lancet Haematol."},{"key":"2146_CR18","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00277-015-2404-1","volume":"94","author":"M Becker","year":"2015","unstructured":"Becker M, Tschechne B, Reeb M, Schwinger U, Bruch HR, Frank M, et al. Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice. Ann Hematol. 2015;94:1553\u20138.","journal-title":"Ann Hematol"},{"key":"2146_CR19","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s00277-016-2668-0","volume":"95","author":"P Mondello","year":"2016","unstructured":"Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, et al. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin\u2019s lymphoma: evidence from a multicenter, retrospective study. Ann Hematol. 2016;95:1107\u201314.","journal-title":"Ann Hematol"},{"key":"2146_CR20","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.","edition":"4"},{"key":"2146_CR21","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol. 1999;17:1244\u201353.","journal-title":"J Clin Oncol"},{"key":"2146_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"2146_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1349-7006.2006.00173.x","volume":"97","author":"M Ogura","year":"2006","unstructured":"Ogura M, Morishima Y, Kagami Y, Watanabe T, Itoh K, Igarashi T, et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci. 2006;97:305\u201312.","journal-title":"Cancer Sci"},{"key":"2146_CR24","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/j.1349-7006.2011.01994.x","volume":"102","author":"M Ogura","year":"2011","unstructured":"Ogura M, Ando K, Taniwaki M, Watanabe T, Uchida T, Ohmachi K, et al. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin\u2019s lymphoma. Cancer Sci. 2011;102:1687\u201392.","journal-title":"Cancer Sci"},{"key":"2146_CR25","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","volume":"31","author":"K Ohmachi","year":"2013","unstructured":"Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013;31:2103\u20139.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-016-2146-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2146-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T21:20:23Z","timestamp":1718918423000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-016-2146-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,29]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["2146"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2146-4","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2016,11,29]]},"assertion":[{"value":"29 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Ogura has received research funding from SymBio; and has received honoraria from Takeda, Mundipharma, Meiji Seika Pharma, and Celgene. Dr. Ishizawa has received research funding from Kyowa Hakko Kirin, MSD, Celgene, and Pfizer; and has received honoraria form Kyowa Hakko Kirin, Chugai, and Takeda. Dr. Maruyama has received honoraria from Eisai, Takeda, Chugai, Janssen, Nippon Kayaku, Celgene, Mundipharma, Sanofi, Kyowa Hakko Kirin, Mochida, and Ono. Dr. Ando has received research funding form Kyowa Hakko Kirin. Dr. Izutsu has received honoraria and research funding from Eisai. Dr. Terui has received honoraria form Janssen. Dr. Tsukasaki has received research funding from Eisai, Celgene, Takeda, and Mundipharma; and has received honoraria from Zenyaku Kogyo, HUYA, and Chugai. Dr. Usuki has received honoraria from Nippon Shinyaku, MSD, Kyowa Hakko Kirin, Novartis, Bristol-Meyer-Squibb, and Dainippon Sumitomo. Dr. Kinoshita has received research funding form Eisai, Solasia, and has received honoraria from Eisai, Zenyaku Kogyo, Janssen, Chugai, and Kyowa Hakko Kirin. Dr. Suzumiya has received research funding from Eisai, Kyowa Hakko Kirin, Chugai, Astellas, and Toyama Chemical; and has received honoraria from Eisai, Chugai, and Takeda. Dr. Nagai has received research funding from CIMIC, Janssen, Mundipharma, Takeda, Bristol-Myers Squibb, and Otsuka; and has received honoraria from Chugai. GY has received honoraria form Takeda, Celgene, and Janssen. Dr. Tobinai has received research funding from Eisai, Chugai, Kyowa Hakko Kirin, Ono, Celgene, Janssen, GlaxoSmithKline, Mundipharma, Takeda, Servier, and AbbVie; and has received honoraria from Eisai, Janssen, Mundipharma, Takeda, Zenyaku Kogyo, and HUYA.All remaining authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}